<DOC>
	<DOCNO>NCT00370227</DOCNO>
	<brief_summary>This study evaluate safety , reactogenicity immunogenicity booster dose pneumococcal conjugate vaccine , co-admin 1st dose 2nd dose MMRV vaccine 12-14 respectively 14-16 month age child prim pneumococcal conjugate vaccine study 105553 . Antibody persistence evaluate 8-10 month completion 3-dose immunization course study 105553 . The immunogenicity , safety reactogenicity 1st 2nd dose MMRV vaccine also evaluate co-admin pneumococcal conjugate vaccine 12-16 month age . The study 3 group . - The 1st group receive booster dose pneumococcal conjugate vaccine + 1st dose MMRV vaccine 12-14 mo age booster dose Infanrix hexa™+ 2nd dose MMRV vaccine 14-16 mo age . - The 2nd group receive booster dose Infanrix hexa™ + 1st dose MMRV vaccine 12-14 mo age booster dose pneumococcal conjugate vaccine + 2nd dose MMRV vaccine 14-16 mo age . - The 3rd group receive booster dose pneumococcal conjugate vaccine + booster dose Infanrix hexa™ 12-14 mo . Subjects offer one dose Priorix™ Varilrix™ 14-16 mo age , outside study .</brief_summary>
	<brief_title>Safety Immunogenicity Study Booster Dose GSK Biologicals ' 10-valent Pneumococcal Conjugate Vaccine</brief_title>
	<detailed_description />
	<mesh_term>Streptococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>healthy male female , 1214 month age time first vaccination , receive least one dose pneumococcal conjugate vaccine study 105553 write informed consent obtain parent/guardian subject . use investigational nonregistered drug vaccine study vaccine within 30 day precede vaccination , plan use entire study period ( active phase safety followup ) . Planned administration/ administration vaccine foreseen study protocol period start one month first dose vaccine ( ) end 4256 day last dose vaccine ( ) . Administration additional pneumococcal vaccine since end study 105553 . Previous vaccination measles , mumps , rubella and/or varicella . History , intercurrent measles , mumps , rubella and/or varicella/zoster disease . Known exposure measles , mumps , rubella and/or varicella/zoster within 30 day prior study start . Immunosuppressive immunodeficient condition . A history seizures neurological disease .</criteria>
	<gender>All</gender>
	<minimum_age>12 Months</minimum_age>
	<maximum_age>14 Months</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Streptococcus pneumonia , pneumococcal conjugate vaccine</keyword>
</DOC>